Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Get Free Report)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $9.96, but opened at $9.28. Curaleaf shares last traded at $9.8868, with a volume of 5,224 shares trading hands.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on CURLF shares. Zacks Research raised Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Citigroup reaffirmed a “buy” rating on shares of Curaleaf in a research note on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Strong Buy”.
Check Out Our Latest Research Report on CURLF
Curaleaf Trading Up 3.9%
Curaleaf (OTCMKTS:CURLF – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.25. Curaleaf had a negative net margin of 2.62% and a negative return on equity of 0.88%. The business had revenue of $340.10 million during the quarter, compared to analysts’ expectations of $332.00 million. As a group, analysts forecast that Curaleaf Holdings, Inc. will post 0.01 EPS for the current fiscal year.
About Curaleaf
Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.
Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.
Featured Stories
- Five stocks we like better than Curaleaf
- 3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
- Gold.com’s Q4 Results Show Why This Stock Is More Than a Gold Bet
- Analog Devices Shows Why AI Is Not the Only Story Driving Chip Demand
- Cathie Wood Trimmed Palantir, But the Bigger Story Is Still Valuation
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.
